Phase II Randomized Study of Early Surgery Vs Multiple Sequential Antiepileptic Drug Therapy for Infantile Spasms Refractory to Standard Treatment
Information source: Office of Rare Diseases (ORD)
Information obtained from ClinicalTrials.gov on June 20, 2008 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Spasms, Infantile; Epilepsy
Intervention: carbamazepine (Drug); corticotropin (Drug); nitrazepam (Drug); pyridoxine (Drug); valproic acid (Drug); Surgery (Procedure)
Phase: Phase 2
Status: Completed
Sponsored by: National Center for Research Resources (NCRR) Official(s) and/or principal investigator(s): W. Donald Shields, Study Chair, Affiliation: University of California, Los Angeles
Summary
OBJECTIVES: I. Evaluate the efficacy of surgical resection of an identifiable zone of
cortical abnormality versus multiple drug therapy in children with infantile spasms
refractory to standard therapy.
II. Assess how infantile spasms interfere with development and whether this is partially
reversible.
III. Determine the predictors of good surgical outcome and whether surgery permanently
controls seizures and improves development.
Clinical Details
Study design: Treatment, Randomized
Detailed description:
PROTOCOL OUTLINE: This is a randomized study. Patients are randomly assigned to 1 of 2
treatment groups. The first group undergoes sequential antiepileptic therapy with
pyridoxine, corticotropin, valproic acid, carbamazepine, and nitrazepam. The sequence of
administration may be altered based on drugs taken prior to entry. Any drug may be omitted
due to medical contraindications or prior use at study doses or higher.
The second group undergoes surgical resection of the zone of cortical abnormality. A
functional hemispherectomy is performed for hemiparesis or diffuse unihemispheric
dysfunction.
If seizures are controlled in the first group at 3 months, the current medication is
maintained; if seizures are not controlled, sequential therapy continues to completion.
Patients experiencing uncontrolled seizures at 6 months cross to surgery.
Surgical patients experiencing uncontrolled seizures at 3 months or persistent seizures after
taper of pre-study antiepileptics cross to drug therapy.
All patients are followed at 6 months and 1, 2, 3, 5, 7, and 10 years.
Eligibility
Minimum age: N/A.
Maximum age: 2 Years.
Gender(s): Both.
Criteria:
PROTOCOL ENTRY CRITERIA:
Disease Characteristics
- Infantile spasms or seizures with diagnosis based on the following: short muscular
contractions leading to flexion or extension; Single or repetitive
electroencephalogram (EEG) consistent with diagnosis, i. e., hypsarrhythmia, modified
hypsarrhythmia, multifocal spike and wave abnormalities; developmental quotient less
than 70
- Zone of cortical abnormality in 1 lobe, contiguous multilobes, or 1 hemisphere;
confirmed by historical, neurological, and physical evidence, including EEG, closed
circuit televised EEG, computed tomography, magnetic resonance imaging, and/or
positron-emission tomography; at least 2 abnormal test/imaging results required
- No treatable seizure etiology such as metabolic disease or infection
Prior/Concurrent Therapy
- Failed standard therapy, i. e., refractory to corticotropin (at least 40 IU/day for 14
days) as follows: persistent infantile spasms OR recurrent spasms after
discontinuation or taper OR complications requiring dose modification
- At least 1 month of standard antiepileptic drug with documented therapeutic blood
levels
Patient Characteristics
- No medical contraindication to surgery
- English-speaking family
Locations and Contacts
Additional Information
Starting date: November 1993
Last updated: June 23, 2005
|